RetiredUnitedHealthcarePolicy CS179LA.D

External beam radiation therapy (EBRT) and Image-guided radiation therapy (IGRT) coverage for various cancers

Defines medical necessity criteria and fraction limits for EBRT (including hypofractionation and special situations) and indications for IGRT; applicable to Louisiana members and providers.

Policy Summary

PayerUnitedHealthcare

PolicyExternal beam radiation therapy (EBRT) and Image-guided radiation therapy (IGRT) coverage for various cancers

Policy CodePolicy CS179LA.D

Change TypeRetiredclinically revised (APBI added) and coding clarifications

Effective DateJune 1, 2025 - March 31, 2026

Next Review DateN/A

Key ActionWhen requesting authorization for palliative bone RT or reirradiation, document prior RT, anatomic site, and chosen fractionation regimen.

SourceLink

POLICY UPDATE CHANGES

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Revised list of medically necessary services when providing EBRT for breast adenocarcinoma; added delivery of up to 5 fractions for accelerated partial breast irradiation (APBI).

Added language that IGRT may be medically necessary during Definitive Treatment when used with 3D-CRT for a condition not listed when documentation shows specified criteria (e.g., DVH comparison, inability to tolerate immobilization, significant target motion, or need for smaller CTV margins).

Coding clarifications added for multiple CPT codes including not reporting megavoltage delivery codes with superficial radiation therapy (77401) and guidance on special dosimetry (77331), special medical physics consultation (77370), and special treatment procedure (77470).

up to 5APBI fractionation added as medically necessary

up to 10

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

fractions for palliative EBRT (bone metastases)

up to 35fractions for NSCLC definitive chemorad

04/01/2026policy retirement date

6,521patients in IGRT meta-analysis

18% vs 9%retreatment rates 8 Gy vs 30 Gy

Coverage Criteria for EBRT and IGRT

Locally Advanced Non-Small Cell Lung Cancer — Definitive Chemoradiation

When providing EBRT, with or without concurrent chemotherapy, for locally advanced (stage III) non-small cell lung cancer (NSCLC), coverage is determined by dose-fractionation and clinical intent. The following criteria consolidate guideline-recommended curative regimens and evidence from randomized trials:

ALL of the following

Treatment intent is definitive/curative for unresectable or inoperable stage III NSCLC (multimodality therapy with curative intent).
Radiation dose prescribed to the planning target volume (PTV) using conventionally fractionated external-beam radiotherapy (fraction size ~2 Gy per fraction).
Total delivered dose is up to 60 Gy given in 2 Gy once-daily fractions (i.e., approximately 30 fractions) or an equivalent conventionally fractionated regimen consistent with professional society guidance.
Concurrent systemic therapy is permitted per standard of care; use of concurrent chemoradiation should follow institutional protocols and guideline recommendations for stage III NSCLC.
Image guidance (IGRT) and appropriate motion management techniques are used as needed to safely deliver curative RT when OARs are in close proximity to high-dose regions or when complex motion management is required (e.g., respiratory gating, tumor tracking).
Per NCCN and ASTRO guidance, IGRT is appropriate when required to deliver curative RT safely.
Use of advanced planning/delivery techniques (IMRT, VMAT, or 3D-CRT) is acceptable; selection should consider target size/location and normal tissue constraints.
Documentation of dose, fractionation, treatment intent, and any use of concurrent systemic therapy must be available for prior authorization and medical record review if requested.

Applicable Codes and Coding Guidance

Applicable CPT/HCPCS codes (referenced)mixed

77014	Computed tomography guidance for placement of radiation therapy fields.
77301	IMRT planning (includes special dosimetry).
77331	Special dosimetry (e.g., TLD, microdosimetry).
77370	Special medical radiation physics consultation.
77385	IMRT delivery; simple.
77386	IMRT delivery; complex.
77387	Guidance for localization of target volume, includes intrafraction tracking.
77399	Unlisted procedure, medical radiation physics, dosimetry and treatment devices.
77401	Radiation treatment delivery, superficial and/or ortho voltage, per day.
77402	Radiation treatment delivery, >= 1 MeV; simple.

1–10 of 21

1/3

Applicable CPT Codes and coding clarificationsCPT

77401	Superficial radiation therapy
77261	Treatment planning
77262	Treatment planning
77263	Treatment planning
77306	Photon dose calculation
77307	Photon dose calculation
77316	IMRT planning
77317	IMRT planning
77318	IMRT planning
77331	Special dosimetry

1–10 of 34

1/4

Hypofractionation fraction size (typical per-fraction cGy values)

Hypofractionation fraction size240-340 cGy per fraction

General definitionHypofractionated radiotherapy: delivery of fewer and larger (>200 cGy) doses of radiation

Typical clinical range (policy)Defined in guideline as EBRT with fraction size between 240 and 340 cGy

APBI fractionation — up to 5 fractions

APBI fractionation limit (policy)Delivery of up to 5 fractions for accelerated partial breast irradiation (APBI)

NCCN preferred APBI dosing30 Gy in 5 fractions

Provider Documentation, Prior Authorization, and Billing Actions

Note

Reference codes do not guarantee coverage; benefits govern

The listed CPT/HCPCS codes are provided for reference only; inclusion does not guarantee coverage and benefit coverage is determined by federal, state, and contractual requirements and applicable laws.

Prior Authorization

Prior authorization — document regimen and prior RT for palliative bone metastases/reirradiation

For palliative EBRT to bone metastases or when considering reirradiation, document the selected conventional palliative regimen and any prior radiation to the anatomic site.

Record prior RT dose to the site and anatomic location.
Document chosen fractionation (examples: 800 cGy x1; 2000 cGy x5; 2400 cGy x6; 3000 cGy x10).
Include clinical assessment of prognosis, normal tissue risk, quality of life, and patient goals.

Background and Evidence Summary

Background: External beam radiation therapy (EBRT) comprises techniques such as three‑dimensional conformal radiation therapy (3D‑CRT), intensity‑modulated radiation therapy (IMRT), and proton beam radiation therapy (PBRT). Image‑guided radiation therapy (IGRT) uses CT‑based or volumetric imaging (for example, CBCT or MVCT) during planning and/or daily treatment to localize targets and improve geometric accuracy, particularly when tight margins, target motion, or proximity to critical structures increase the risk of geographic miss. Specialty practice parameters recommend IGRT when targets are near critical structures, subject to daily internal motion, require narrow margins, abut previously irradiated areas, or when dose escalation or highly conformal techniques are used.

Definitions and Key Terms

Definitive Treatment definition

DefinitionDefinitive Treatment: Radiation treatments for cancer with a curative intent

ContextApplies to radiation delivered with curative (not palliative) intent

Source exampleLandsteiner et al., 2023 (definition cited in policy)

Limited Metastatic Disease (prostate-specific) definition

Definition (prostate-specific)Absence of visceral metastasis or fewer than four bone metastases with no metastasis outside the vertebral bodies or pelvis

ScopeUsed to define candidates for definitive treatment in patients with limited metastatic prostate cancer

Policy Summary

PayerUnitedHealthcare

PolicyExternal beam radiation therapy (EBRT) and Image-guided radiation therapy (IGRT) coverage for various cancers

Policy CodePolicy CS179LA.D

Change TypeRetiredclinically revised (APBI added) and coding clarifications

Effective DateJune 1, 2025 - March 31, 2026

Next Review DateN/A

Key ActionWhen requesting authorization for palliative bone RT or reirradiation, document prior RT, anatomic site, and chosen fractionation regimen.

SourceLink

On This Page

ASTRO external beam PBI recommended schedule3000 cGy in five once-daily fractions (delivered on nonconsecutive days within two weeks)

Prior Authorization

Prior authorization — document nodal risk and rationale for pelvic fields (prostate)

When delivering prophylactic whole‑pelvic radiotherapy (WPRT) for high‑risk prostate cancer or expanded salvage fields, document the estimated nodal risk and clinical rationale to support pelvic nodal field selection.

Document estimated nodal risk (e.g., ≥20%) and rationale for WPRT versus prostate‑only RT.
Record planned duration of concurrent androgen deprivation therapy (ADT) when applicable.

Note

Prior authorization — no explicit requirements stated

No additional explicit prior authorization requirements are specified in the cited policy extracts.

Billing Rule

Coding-related PA and reporting guidance — follow specified code rules

Follow the policy's coding and reporting clarifications when preparing authorizations and claims; certain delivery and special‑service codes have specified reporting rules.

Do not report megavoltage delivery or planning codes with superficial radiation therapy (CPT 77401) as listed.
Use CPT 77331 for special dosimetry scenarios (e.g., measurements outside normal planning parameters).
Report CPT 77370 and 77470 only under the documented single‑report circumstances described in the coding clarifications.

Documentation Required

Palliative bone metastases — document justification when exceeding standard fractions or reirradiating

When delivering more than standard single‑ or multi‑fraction palliative regimens for bone metastases, especially in a reirradiation context, document the justification and prior treatment history.

If treating a previously irradiated site (policy allows >10 fractions in that context), include prior dose and timing of prior RT.
Support regimen choice with guideline‑recommended options and patient‑specific factors per ASTRO/ESTRO.

Step Therapy

Step consideration — single vs multi‑fraction palliative RT (document rationale)

Weigh single‑fraction (8 Gy) versus multi‑fraction regimens for palliative bone RT by documenting considerations of acute toxicity and higher retreatment risk with single fraction treatment.

Note that single 8 Gy has less acute toxicity but higher retreatment rates (18% vs 9% in Hartsell RCT).
Document why a selected regimen is preferred for the individual patient (prognosis, symptoms, logistics).

Prior Authorization

Salvage RT timing — document PSA and risk when requesting salvage radiation

For salvage radiation after radical prostatectomy, document PSA trends and timing; offer salvage RT when PSA is ≤ 0.5 ng/mL and consider earlier salvage (PSA < 0.2 ng/mL) for high‑risk patients.

Include PSA values and trajectory in the record when requesting authorization for salvage RT.
Document any intent to include regional nodes or use ADT alongside salvage fields.

Note

Step therapy — none specified

No step therapy requirements are specified in the cited policy extracts.

Note

No action specified

This inventory slot has no provider action content in the cited extracts.

Documentation Required

Documentation required to support special services (77331, 77370, 77470)

When billing for special services, support use of CPT 77331, 77370, and 77470 with contemporaneous documentation that meets the policy's described circumstances.

CPT 77331: document special dosimetry measurements outside normal planning/calc parameters (e.g., abutting fields, unusual anatomic situations).
CPT 77370: document the complex physics consultation reason (listed scenarios) and report once when met.
CPT 77470: document the special treatment procedure justification and report once when criteria apply.

Documentation Required

Document regimen selection and patient‑specific assessments

Document the clinical rationale for regimen selection, including which guideline‑recommended dose/fraction option was chosen and assessment of prognosis, prior RT doses, normal tissue risks, quality of life, and patient goals.

Record which guideline regimen (example palliative options) was selected and why.
Include evaluation of prior radiation exposure to the site and normal tissue dose constraints.

Documentation Required

Imaging and IGRT documentation — frequency, modality, and DVH considerations

Document imaging frequency and any use of IGRT or DIBH; include DVH evaluations for organs at risk (e.g., heart, lung) and note NCCN's recommendation for at least weekly imaging verification.

Specify imaging modality and frequency (e.g., daily CBCT, weekly volumetric imaging).
Provide DVH comparisons and note use of DIBH when applicable to show normal tissue sparing.

Documentation Required

Quality control and immobilization documentation for CT‑based IGRT

Maintain and document quality control protocols for CT‑based IGRT systems, including geometric accuracy assessments and immobilization/positioning decisions as margins tighten.

Document daily QC procedures and geometric accuracy checks for image‑guidance systems.
Record immobilization devices chosen and rationale (comfort, reproducibility, effect on anatomy).

Documentation Required

Support medical necessity for IGRT with 3D‑CRT — required documentation

When IGRT is used with 3D‑CRT for a condition not explicitly listed as medically necessary, include documentation demonstrating at least one supporting condition such as DVH comparison showing normal tissue sparing, inability to tolerate immobilization, significant target motion on imaging, or the need for smaller CTV margins.

Attach comparison plans and DVHs (e.g., DIBH vs free breathing) when claiming normal tissue sparing.
Document CT simulation intolerance or imaging evidence of target motion if applicable.

Denial Risk

IGRT denial risk — lack of documented indication (superficial treatment or bony alignment)

IGRT will likely be denied as medically unnecessary when the policy's IGRT criteria are not met; common examples include superficial skin treatments and use solely to align bony landmarks without implanted fiducials.

Do not request IGRT authorization for superficial radiation therapy or electronic brachytherapy unless another IGRT indication is documented.
Avoid using IGRT claims solely for bony alignment without implanted fiducials.

Denial Risk

Retreatment risk with single 8 Gy — document when selecting single‑fraction palliative RT

Be aware that single‑fraction 8 Gy has higher retreatment rates than multi‑fraction regimens; document expected retreatment risk and rationale when selecting single‑fraction palliative RT.

Hartsell RCT: retreatment rate 18% for single 8 Gy vs 9% for 30 Gy/10 fractions — include this consideration in clinical rationale.
Document patient factors (prognosis, mobility, access) that influenced regimen choice.

Denial Risk

High‑dose NSCLC RT — document justification; 74 Gy linked to worse outcomes

Deviation from the standard 60 Gy definitive chemoradiation dose for stage III NSCLC (e.g., escalation to 74 Gy) is associated with worse survival and increased toxicity; document strong justification if proposing higher doses.

RTOG 0617 showed inferior overall survival with 74 Gy vs 60 Gy; include trial‑based justification for any dose escalation.
Expect clinical review or potential denial without evidence supporting deviation from 60 Gy.

Note

No additional payer denial triggers specified; emphasize daily QC

The extract includes no explicit payer‑level denial triggers beyond the examples already provided; continue to emphasize daily QC and geometric accuracy for tight PTV margins as operational safeguards.

Denial Risk

Coverage determinations must follow federal, state, or contractual benefit terms

When applying this policy, verify and reference applicable federal, state, or contractual benefit requirements because those terms govern in the event of conflict; failure to follow governing benefit terms may result in denial.

Parker et al., 2018 (definition cited in policy)

Conventional palliative RT regimens — examples

Examples of conventional palliative RT regimens800 cGy in 1 fraction; 2000 cGy in 5 fractions; 2400 cGy in 6 fractions; 3000 cGy in 10 fractions

Spine-specific options800 cGy x1; 1600 cGy x2; 2000 cGy x5; 3000 cGy x10 (for cord compression when surgery not indicated)

Reirradiation examplesFor reirradiation to same site: 800 cGy x1 or 2000 cGy x5 or 2400 cGy x6 or 2000 cGy in 8 fractions

Hypofractionation — definition and examples

DefinitionRadiation delivered in fewer, larger fractions (policy defines hypofractionation as fraction size between 240 and 340 cGy)

Breast example26 Gy in 5 fractions (Brunt et al.) — five‑fraction whole-breast schedules studied

START-supported example40 Gy in 15 fractions — supported by START trials with long-term follow-up

Hypofractionated Whole-Breast Irradiation (HF-WBI) — common regimens

Common HF‑WBI regimens40 Gy in 15 fractions; 42.5 Gy in 16 fractions

Short-course whole‑breast 5‑fraction regimens26–27 Gy in 5 fractions (one‑week schedules studied in randomized trials)

APBI external‑beam option3000 cGy in 5 fractions for selected patients (ASTRO recommendation)

Moderate hypofractionation (prostate) — fraction sizes and examples

Moderate hypofractionation fraction sizes (prostate)Approximately 2.5–3.4 Gy per fraction (policy example range)

Example regimen (non-inferior)60 Gy in 20 fractions (CHHiP/Dearnaley) — shown non‑inferior to conventional fractionation

Higher‑fraction size cautionTrials such as HYPRO (3.4 Gy x19) reported higher acute GU/GI toxicity; regimen selection should consider toxicity tradeoffs

IGRT definition — CT-based or volumetric imaging during planning and/or daily treatment

IGRT definitionUse of CT‑based or volumetric imaging (e.g., CBCT, MVCT) during planning and/or daily treatment to localize targets and adjust patient positioning

Primary aimDetect and correct positional uncertainties to improve geometric accuracy as PTV margins tighten

Typical modalitiesCone‑beam CT (CBCT) and other onboard CT‑based volumetric imaging systems

4D-IG / 4D-CT definition — respiration-correlated imaging and planning methods

4D‑IG / 4D‑CT definitionRespiration‑correlated imaging and planning methods that capture tumor motion over the respiratory cycle to allow motion management and potential margin reduction

PurposeUsed for planning and daily guidance to quantify and mitigate respiratory tumor motion

Effect on marginsPolicy cites potential margin reductions of ~37%–47% with 4D strategies (Korreman et al.)

IGRT short definition (duplicate inventory term)

Short IGRT definitionImage‑guided radiation therapy (IGRT) — use of imaging to localize and verify target position prior to treatment delivery

When usedParticularly applicable to highly conformal techniques (3D‑CRT, IMRT, PBRT) and when targets are near critical structures

Imaging examplesVolumetric CT‑based systems such as CBCT and MVCT

Motion management techniques — examples (gating, tracking, compression)

Motion management techniquesRespiratory gating, tumor tracking, abdominal compression, full bladder, deep inspiration breath hold (DIBH)

PurposeTechniques used to account for intra‑ and inter‑fraction target movement and to reduce required PTV margins

Policy examplesDIBH used with IGRT to reduce heart/lung exposure during breast RT; beam gating and tracking for lung/liver SBRT